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Glucocorticoids influence many physiological pro-
cesses, and in particular apoptosis, often with opposite
effects depending on the cell type examined. We found
that during fibrosarcoma development there is a strong
increase in apoptosis at the tumor stage, which is re-
pressed by dexamethasone to levels observed in normal
fibroblasts. The anti-apoptotic Bcl-2 family protein
Bcl-xL is induced by dexamethasone at the transcrip-
tional level at all stages of fibrosarcoma development.
The ligand-activated glucocorticoid receptor (GR) acti-
vates the Bcl-x promoter in transient transfection exper-
iments, and GR binds to specific Bcl-x promoter se-
quences in vitro and in vivo. Furthermore, a GR
antagonist abolishes this effect, indicating that Bcl-xL
induction is mediated by GR. Importantly, exogenous
Bcl-xL inhibits apoptosis and caspase-3 activity in fibro-
sarcoma cells to levels found in dexamethasone-treated
fibrosarcoma cells. We conclude that Bcl-xL is a key
target mediating the anti-apoptotic effects of glucocor-
ticoids during fibrosarcoma development. These obser-
vations provide further understanding of the molecular
basis of glucocorticoid regulation of cell death during
tumorigenesis.
Glucocorticoids exert different effects on apoptosis and cell
growth depending on the tissues examined. In some cell types,
for example thymocytes and some leukemia cell lines, treat-
ment with glucocorticoids induces apoptosis (1). This has led to
their common use as chemotherapeutic agents in lymphomas
and leukemias (2). In contrast, glucocorticoids have been re-
ported to inhibit apoptosis in a number of other cell types,
including glioma and astrocytoma cell lines (3), fibroblasts (4),
hepatoma cells (5), gastric cancer cell lines (6), and mammary
epithelial cells (7, 8).
The glucocorticoid receptor (GR)1 belongs to a superfamily of
transcription factors that includes receptors for steroid and
thyroid hormones, retinoic acid, and vitamin D3 (9). GR is
normally localized in the cytoplasm in a non-active state in a
complex that includes Hsp90. Upon hormone binding, GR
changes conformation and migrates to the nucleus, where it
induces or represses transcription by binding to specific DNA
sequences on target genes (10).
Apoptosis, triggered by a variety of intra- and extracellular
signals, is important for normal development, to maintain tis-
sue homeostasis, and as a defense strategy against the emer-
gence of cancer (11, 12). The apoptotic program is executed by
a family of cysteine proteases called caspases, which are acti-
vated by proteolytic cleavage (13, 14). Once activated, effector
caspases cleave a variety of cellular substrates including struc-
tural components, regulatory proteins, and other caspases, re-
sulting in the orchestrated collapse of the cell characteristic to
apoptosis.
Bcl-2 family proteins play critical roles in the control of
apoptosis. Two major groups of Bcl-2 family proteins exist; the
pro-survival members, including Bcl-2, Bcl-xL, Bcl-w, Mcl-1,
etc., and the pro-apoptotic members, including Bax, Bak, Bok,
etc. (see Ref. 15 for review). The ratio between these two groups
of family members determines whether a cell will live or die.
Downstream of this checkpoint lie the caspase pathway and
mitochondria dysfunction, major execution events that lead to
irreversible cell death (16). Alterations in the expression of
anti-apoptotic members such as Bcl-2 and Bcl-xL have been
implicated in tumorigenesis in both clinical cases and trans-
genic models (17). In addition, Bcl-2 members are also impor-
tant determinants of anticancer drug sensitivity (18).
The conversion of a normal cell to a neoplastic one occurs in
multiple steps (19), and one approach to studying this process
has been to employ transgenic mice (20). Mice carrying the
bovine papillomavirus type I genome develop dermal fibrosar-
comas in a process that involves distinct proliferative stages.
These are the normal fibroblasts (NF), and then two histolog-
ical grades of hyperplasia, mild fibromatosis (MF) and aggres-
sive fibromatosis (AF). Finally, at lower frequency, dermal
fibrosarcomas (FS) develop (21). The first molecular distinction
between the AF and the FS cells to be identified was a dramatic
increase in ligand-dependent GR transcriptional activity in FS
cells (22). This increase does not result from changes in the
intracellular levels of GR, hormone-dependent nuclear trans-
location, or specific DNA binding activity, all of which are
unaltered throughout the progression. Moreover, analysis of
the tumors formed in mice upon inoculation of AF or FS cells
indicates a direct correlation between GR transcriptional ac-
tivity and tumorigenic potential (22).
To understand cancer progression it is important to deter-
mine the mechanisms by which signaling proteins influence
proliferation and apoptosis at different stages of the tumori-
genic process. Here we have examined the effects of dexa-
methasone on apoptosis in the multistep tumorigenic pathway
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of fibrosarcoma development. Our observations point to Bcl-xL
as a key GR target mediating the inhibition of apoptosis during
fibrosarcoma progression.
EXPERIMENTAL PROCEDURES
DNA Plasmid Constructions—The plasmid containing 3.2 kb (3292
to 94) of the 5-region of the murine Bcl-x promoter linked to the
luciferase reporter gene (23) was a kind gift of Gabriel Nun˜ez (Ann
Arbor, MI), and was designated Bcl-x(3.2). Serial promoter deletion
fragments were cloned into pGL2-basic (Promega) as follows: Bcl-x(2.8)
(2829 to 94) as a BglII and HindIII fragment; Bcl-x(0.6) (679 to
94) by SmaI and partial HindIII digestion; Bcl-x(0.2) (299 to94) as
an XmnI and HindIII fragment, and Bcl-x(0.1) (199 to 094) as a KpnI
and HindIII 110-bp fragment.
Fragments containing the putative GREs from the Bcl-x promoter
were cloned into a TK109-luciferase reporter construct: RE1 contains
sequences of the murine Bcl-x promoter from 2963 to 2268. This
fragment was amplified by PCR using Bcl-x(3.2) as template and the
oligonucleotides A (5-GTTTCCCAAAAGGATCCAATG-3) and C (5-
AAATGCGGATCCTGACTGACTG-3). The product was digested with
BamHI and inserted into TK109-luciferase. RE2 contains sequences
from 2963 to 2826, which were amplified by PCR using the oligo-
nucleotides A and D (5-CTGGTTATGTAGCTGTGGGCTGCC-3). The
PCR product was digested with BamHI and BglII. RE3 contains se-
quences from 2349 to 2268 of the Bcl-x promoter, which were am-
plified by PCR using the oligonucleotides B (5-AAGTGGATCCTC-
CTATGCTAC-3) and C. The product was digested with BamHI.
The putative GREs from the Bcl-x promoter were mutated using the
following oligonucleotides (nucleotides that were changed are under-
lined) and their reverse complements: P1 (5-CTCTGTGGCCAACAGT-
CCATTCTGCGAAAGACGGGAAAGTTGC-3), P2 (5-GCTGTGCAGA-
AGACCAGCTTTTTCCTGAGGCCATGTTATCC-CACAGCCAGG-3),
P3 (5-GCTACATAGATTGAGGCCAGACTCGGCTGAAAAACTG-3).
The QuikChange XL site-directed mutagenesis kit (Stratagene) was
used following the instructions of the manufacturer. All mutations were
confirmed by DNA sequencing.
The fragment of murine Bcl-xL cDNA encompassing the coding re-
gion was amplified by PCR from the total cDNA of NF cells using HiFi
polymerase (Roche Applied Science). This fragment was cloned into
pIRES2-eGFP (Clontech). Absence of mutations within the insert was
confirmed by sequencing in all cases.
Cell Culture and Transient Transfections—Cultures were estab-
lished from skin and tumor tissues and maintained as reported previ-
ously (22). Several cultures were tested from each stage of the tumor-
igenic process: normal fibroblasts (23784, 40950); mild fibromatosis
(14249, 39614, 27877); aggressive fibromatosis (BPV3, BPV7, BPV21);
fibrosarcomas (BPV1, BPV22, BPV2, BPV11). For experiments involv-
ing steroid hormone treatments, cells were maintained in medium
containing charcoal-stripped serum (24). COS-7 cells were also main-
tained as above. Cell viability was determined by trypan blue dye
exclusion (25).
Cells were transiently transfected using the DEAE-dextran method
and the -galactosidase expression vector 6RZ as internal control for
efficiency of transfection as described previously (22). After exposure to
the DNA/DEAE-dextran mixture, the cells were incubated for 36 h in
medium containing charcoal-stripped serum with or without 100 nM
dexamethasone (Sigma). The GR antagonist RU 40555 was kindly pro-
vided by Roussel-Uclaf (Romainville, France). Luciferase activity was
measured according to the instructions of the manufacturer (Promega).
RNA Isolation and Northern Blot Analysis—Total RNA was isolated
using the SV Total RNA isolation system (Promega) according to the
instructions of the manufacturer. Northern blot analysis was performed
using conventional techniques. The probe encompassing 725 bp of the
Bcl-xL cDNA was labeled using a Random Primed DNA labeling kit
(Roche Applied Science) following the instructions of the manufacturer.
Finally, the membrane was exposed to x-ray film (Kodak X-Omat AR).
Preparation and Analysis of Cell Extracts—Cells were harvested by
centrifugation in 40 mM Tris-HCl, pH 7.8, 10 mM EDTA, and 150 mM
NaCl, washed in ice-cold phosphate-buffered saline, and re-pelleted and
frozen in liquid nitrogen. Cells were resuspended in lysis buffer (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate,
1% Nonidet P-40, 10 g/ml phenylmethylsulfonyl fluoride, 1 g/ml
aprotinin/leupeptin/pepstatin A), incubated on ice for 25 min, and cen-
trifuged for 20 min at 14,000 rpm. Equal amounts of extract protein (30
g) were analyzed by immunoblot analysis as described previously (22).
Anti-Bcl-2 (Oncogene), anti-Bcl-xL/S (Transduction Laboratories), anti-
Bax (Zymed Laboratories Inc.), anti--actin (Sigma), and anti-tubulin
(Sigma) were used as primary antibodies, followed by incubation with
the corresponding secondary antibody (horseradish peroxidase-conju-
gated; Bio-Rad). Protein-antibody complexes were visualized by an en-
hanced chemiluminescence immunoblotting detection system (Amer-
sham Biosciences).
Gel Retardation Assays—Analysis of DNA-protein interactions was
performed as described (22). The following oligonucleotides were used:
consensus GRE-TAT (22), P1 (5-TGGCCAACAGTACATTCTGTGAAA-
GAC-3), P2 (5-TGTGCAGAAGAACAGCTTTTTCC-TGAGGCCATGT-
TGTCCCACAG-3), and P3 (5-ATAGATTGAGGACAGACTGGGCTG-
AAA-3); nonspecific, N (5-AGGATAACGGAGGCTGGGTAGGTGCAC-
3). To assess specificity of DNA binding, 50-fold molar excess of
unlabeled oligonucleotide (consensus GRE, specific (S) or same as la-
beled oligonucleotide) or 200-fold molar excess of a nonspecific oligonu-
cleotide (N) was added to the reaction prior to addition of the labeled
probe.
Caspase Enzyme Activity Assay—Caspase assays were performed
using a protocol based on the QuantiZyme™ assay system (Biomol).
Cells were lysed in buffer Q (50 mM HEPES, pH 7.4, 0.1% CHAPS, 0.1
mM EDTA, 0.1 mM dithiothreitol) for 30 min on ice followed by centri-
fugation at 14,000 rpm for 10 min at 4 °C. Equal amounts of protein (30
g) were added in triplicate to wells in a 96-well plate and equilibrated
to 37 °C for 15 min after the addition of assay buffer (50 mM HEPES pH
7.4, 0.1% CHAPS, 1 mM EDTA, 10 mM dithiothreitol, 100 mM NaCl, 10%
glycerol). Fluorogenic peptide substrates selective for caspase-1 (YVAD)
or caspase-3 (DEVD) (final concentration 1 mM) were added to each well
and incubated at 37 °C for 6 h. For controls, the caspase inhibitors
Ac-YVAD-CHO or Ac-DEVD-CHO, respectively, were used at a final
concentration of 0.5 M. Absorbance of the samples at 405 nm was
measured using a colorimetric plate reader (MRX) immediately after
addition of the substrate and after 6 h. The change in absorbance of
each sample (minus the inhibitor control) over the 6-h period was taken
as the specific caspase activity.
Chromatin Immunoprecipitation (ChIP) Assay—Cells were main-
tained in 10-cm dishes in medium containing charcoal-stripped serum
for at least 16 h and treated with or without 100 nM dexamethasone for
1 h. The ChIP assay was performed as described previously (26) except
that the final samples were resuspended in 30 l of water, and 2–4 l
of each sample was used for PCR amplification (30 cycles) with the rTaq
DNA polymerase (TaKaRa). The antibody used against GR was sc-
1002X, and sc-751 against cyclin A was used as a negative control (both
from Santa Cruz Biotechnology). The primers for the PCR were 5-
CCCAAAAGGATAGAATGAACTCTG-3 and 5-CTGGTTATGTAGCT-
GTGGGCTGCC-3, which amplify a 247-bp fragment corresponding to
murine Bcl-x sequence2976 to2730 from the transcription start site
(GenBankTM accession number AF 088904). As negative control the
primers 5-TGGGCTGGCTCCCTGGTCAG-3 and 5-CCTCGGTCACG-
GATCTTAGGC-3, which amplify a 112-bp fragment corresponding to
murine Bak sequence 960 to 848 (GenBankTM accession number
Y 13232), were included in the same PCR reactions.
RESULTS
Cell Death Is Reduced by Dexamethasone Treatment—Cell
proliferation increases during fibrosarcoma development in
vivo (27) and in cultured cells (21), and it is inhibited by
dexamethasone, a GR agonist (53). We examined the effects of
glucocorticoids on cell death during fibrosarcoma progression.
We used low-passage primary cell lines representative of the
four stages in this multistep pathway: NF, MF, AF, and FS
TABLE I
Stages of murine fibrosarcoma development
The integrated bovine papillomavirus type-1 (BDV-1) transgene pres-
ent in NF cells is excised and transcribed in MF, AF, and FS cells.
However, E5 and E6 oncogene products are detectable only in the latter
two cell types (21). All cells forming tumors in vivo exhibit FS pheno-
type (22). Increased activity of cellular AP-1 components JunB and
c-Jun is apparent in AF and FS cells (22, 50), but dramatically in-
creased GR activity is unique to the tumor cells (22).
NF MF AF FS
BPV-1 RNA    
E5, E6    
Tumor    
JunB, c-Jun    
GR activity    
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cells (see Table I). Cells from each stage were cultured in the
absence and presence of dexamethasone, and cell growth was
observed for 7 days at 24-h intervals. In the absence of hor-
mone, cells from the earlier stages of the progression prolifer-
ated at a lower rate, as reported previously, whereas FS cells
increased rapidly in number (21). Cells cultured in the pres-
ence of dexamethasone appeared flattened (data not shown)
and were fewer in number. Trypan blue exclusion was used as
a marker for viability of the cells. The number of dead cells,
calculated as a percentage of total population at each of the
progression stages (Fig. 1A, dead cells at day 7), indicated that
the extent of cell death was higher in the tumor cells than in
the primary cells and that dexamethasone reduced the number
of dead cells, particularly among FS cells. Fig. 1B shows the
proportion of dead FS cells on each day of culture. Thus dexa-
methasone exerts a protective effect on FS cells.
To assess whether the observed cell death reflected apopto-
sis, we measured the caspase activity in cells from all stages of
fibrosarcoma development. Caspase-3 has been shown to be
one of the key effectors of apoptotic cell death (28), whereas
caspase-1 is involved in inflammatory responses and also in
some forms of apoptosis (29). In the absence of hormone there
was an increase in both caspase-1 and caspase-3 activity dur-
ing tumor progression (p  0.01), particularly at the fibrosar-
coma stage (Fig. 1, C and D). Upon dexamethasone treatment,
caspase-3 activity was 50% reduced in FS cells (p  0.005),
suggesting an inhibition of apoptosis. In contrast, caspase-1
activity was not affected by the presence of hormone. In addi-
tion, when we examined the extent of cell death by DNA frag-
mentation analysis, we detected a high degree of DNA degra-
dation in the FS cells, which was abolished by hormone (data
not shown). These results confirm that there is a strong in-
crease in apoptosis at the tumor stage of fibrosarcoma devel-
opment and that this is reduced by dexamethasone.
Changes in the Expression of Bcl-2 Family Proteins during
Fibrosarcoma Development—Bax appears to be one of the ma-
jor pro-apoptotic Bcl-2 proteins that act as death effectors in
fibroblasts, and Bcl-2 and Bcl-xL serve as inhibitors of Bax (30).
Furthermore, Bcl-xL has been found to be regulated by dexa-
methasone in some cell types (8, 31). Therefore, to investigate
changes in the level of expression of Bcl-2 family proteins that
might contribute to the regulation of apoptosis during fibrosar-
coma development, we examined the expression levels of these
proteins in the absence and presence of dexamethasone by
immunoblot analysis (Fig. 2). NF and MF cells expressed sim-
ilar levels of the Bcl-2 family members examined hence only
MF results are shown in this figure. Expression of the pro-
apoptotic protein Bax was elevated in FS cells, but its protein
levels were not affected by dexamethasone (Fig. 2A). The in-
creased expression of Bax protein correlates with increased
apoptosis in FS cells. However, the hormone-dependent inhibi-
tion of apoptosis we observed in FS cells does not correlate with
Bax levels.
Analysis of the expression of anti-apoptotic proteins (Fig. 2B)
showed that Bcl-2 migrated as a doublet and remained con-
stant in all cell types throughout tumor progression. In con-
trast, Bcl-xL expression clearly decreased during fibrosarcoma
progression. However, in the presence of dexamethasone its
expression was strongly induced, correlating with the much
reduced level of apoptosis in dexamethasone-treated FS cells
(Fig. 1).
The combination of changes in the expression levels of apo-
ptotic proteins in FS cells, together with elevated caspase-3
activity, correlates with the increase in apoptosis at the tumor
stage, suggesting that Bcl-2 proteins play a role in regulating
apoptosis during fibrosarcoma development. Furthermore,
Bcl-xL induction in response to hormone in FS cells makes
Bcl-xL a candidate for mediating the reduction in apoptosis at
the tumor stage.
Bcl-xL Expression Is Induced by Dexamethasone—A more
detailed analysis of expression of Bcl-xL protein during fibro-
sarcoma progression showed a clear increase in the fold in-
duction of the protein by dexamethasone as fibrosarcoma
progresses (Fig. 3A). This pattern of hormone-dependent induc-
tion of expression correlates with the transition in GR trans-
activation activity observed during fibrosarcoma progression
(22) and suggests that GR might be involved directly in Bcl-xL
regulation. The analysis presented involved representative cell
cultures from the four stages of the pathway (NF 40950, MF
FIG. 1. Effects of dexamethasone (Dex) on cell death during
fibrosarcoma development. A, the number of dead cells as a percent-
age of total population of NF, MF, AF, and FS cells. Cells from each
stage of fibrosarcoma progression were plated at 2  104 cells/well 24 h
prior to treatment with (solid bars) or without (shaded bars) 100 nM
dexamethasone. Values represent the mean percentage of total cells
counted in triplicate, within one representative experiment (repeated
three times). Error bars represent standard deviation in all figures. B,
dead FS cells on each day of culture. C and D, caspase-1 and caspase-3
enzyme activities in NF, MF, AF, and FS cells. Duplicate nonconfluent
dishes of cells were untreated or treated with dexamethasone for 24 h.
Values represent the average of three independent experiments.
Caspase activity is in absorbance units (102).
FIG. 2. Expression of endogenous Bcl-2 family proteins in MF,
AF, and FS cells. Immunoblot analysis of pro-apoptotic (Bax) (A) and
anti-apoptotic (Bcl-2, Bcl-xL) (B) from MF, AF, and FS cells untreated
() or treated () for 24 h with 100 nM dexamethasone (Dex). Cell
extracts were probed with antibodies against various members of the
Bcl-2 family (for details see “Experimental Procedures”).
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14249, AF BPV3, FS BPV1). However, we assayed the expres-
sion of Bcl-xL in two or more independent cell lines from each
stage (see “Experimental Procedures”) and found that all lines
derived from a particular stage displayed consistent results. To
determine the time course of Bcl-xL induction in FS cells, we
examined protein levels at various times after dexamethasone
treatment (Fig. 3B). Induction of Bcl-xL protein could be de-
tected as early as 2–4 h following exposure to the hormone and
remained elevated for 24 h.
Bcl-x Transcription Is Induced by Dexamethasone—The
rapid increase in the level of Bcl-xL protein by dexamethasone
in FS cells suggested that this induction occurred at the tran-
scriptional level. Therefore, we examined Bcl-x mRNA expres-
sion after exposure to dexamethasone in all stages of fibrosar-
coma development. Northern blot analysis revealed a major
band of 3-kb mRNA in all cell stages (Fig. 4A), as reported
previously (32). In the absence of hormone, the expression level
of the Bcl-x transcript was reduced during tumor development,
similar to the observed decrease in protein levels. Bcl-x mRNA
was increased by the presence of dexamethasone.
To investigate the regulation of Bcl-x promoter activity by
dexamethasone, we transiently transfected a luciferase re-
porter construct containing a 3.2-kb genomic fragment of the
murine Bcl-x promoter, Bcl-x(3.2), together with a -galacto-
sidase expression plasmid to normalize for transfection effi-
ciency, into cells from each stage of fibrosarcoma progression.
In the absence of dexamethasone, the activity of the promoter
decreased from NF to FS cells (Fig. 4B) suggesting that Bcl-xL
protein expression decreases during tumor development in the
absence of dexamethasone, primarily as a result of reduced
Bcl-x transcription. Upon dexamethasone treatment, promoter
activity was strongly increased in FS cells, indicating that
glucocorticoids induce Bcl-x transcription (Fig. 4B). Various
concentrations of dexamethasone were tested, and concentra-
tions as low as 1010 M significantly increased Bcl-x promoter
activity (p  0.005) (Fig. 4C).
To assess whether the induction of Bcl-x transcription by
dexamethasone is dependent on GR, we tested the effect of the
GR antagonist RU 40555 on transcriptional regulation of the
Bcl-x promoter. In FS cells, dexamethasone-dependent Bcl-x
promoter activity was inhibited by RU 40555 in a dose-depend-
ent manner (Fig. 4D), whereas it did not have any effect by
itself, demonstrating a requirement for transcriptionally active
GR to induce Bcl-x expression.
GRE-like Sequences in the Bcl-x Promoter Mediate GR Acti-
vation—To understand further the transcriptional regulation
of Bcl-x expression by dexamethasone, we searched for poten-
tial sequences within the Bcl-x promoter that confer hormone
responsiveness. A series of luciferase vectors were constructed
containing 5 fragments of the 3.2-kb region of the Bcl-x pro-
moter (Fig. 5A) and were transiently transfected into FS cells.
Analysis of these fragments showed a clear reduction in the
ability of the promoter to respond to dexamethasone, from
around 8–10-fold induction using the 3.2-kb fragment to a
small but significant (p  0.005) induction using the most
proximal region (Fig. 5B). The highest induction from the latter
was obtained using Bcl-x(0.1), suggesting that this region
(199 to 94) contains a proximal weak glucocorticoid re-
sponse element (GRE). Although this fragment does not con-
tain classical consensus GRE sequences, it does contain puta-
tive binding sites for factors known to interact with GR, such as
C/EBP (33) and Oct-1 (34). However, it appears that the major
hormone-inducible promoter sequences are located within
3292 to 679.
To investigate further the glucocorticoid-responsive se-
quences within the Bcl-x promoter, the murine genomic Bcl-x
sequence (GenBankTM accession number AF 088904) was
screened for potential GR binding sites by computer analysis
(MatInspector program, San Diego Workbench). Three candi-
date sequences, P1–P3 (with P2 containing two adjacent sites),
were identified with some homology to the consensus GRE
sequence GGTACANNNTGTTCT (35) in the sequence between
2944 and 2316 (Fig. 5C). To test whether these putative
GREs (or GRE-like elements) are sufficient to mediate hor-
mone induction, three fragments containing these sequences
(RE1, 2963 to 2268, RE2, 2963 to 2826 and RE3, 2349
to 2268, Fig. 5C) were cloned into a luciferase reporter plas-
mid driven by a TK109 promoter (TK109-luciferase). All three
reporter plasmids displayed a clear induction of transcription
in response to dexamethasone treatment (Fig. 5D). The largest
FIG. 3. Bcl-xL protein expression during fibrosarcoma pro-
gression following dexamethasone (Dex) treatment. A, immuno-
blot analysis of Bcl-xL protein from NF, MF, AF, and FS cells untreated
() or treated () with 100 nM dexamethasone for 24 h. Cell extracts
from each stage of fibrosarcoma progression were probed with a rabbit
antibody against Bcl-xL. B, time course of Bcl-xL protein induction in FS
cells in response to dexamethasone for the indicated amount of time
(0–24 h). All cells were harvested 48 h after plating and were growing
exponentially.
FIG. 4. Regulation of Bcl-x transcription by dexamethasone
(Dex). A, cells from the various stages of fibrosarcoma progression were
untreated () or treated () with 100 nM dexamethasone for 4 h.
Northern blot analysis of Bcl-x mRNA levels using a 725-bp fragment
from the Bcl-xL cDNA (IMAGE 1395857) as probe. The membrane was
also probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
B, expression of the Bcl-x(3.2) luciferase reporter construct in NF, MF,
AF, and FS cells. The cells were either untreated (black bars) or treated
for 36 h with 100 nM dexamethasone (shaded bars). Transcriptional
activity of endogenous GR was analyzed. In all transfection experi-
ments, luciferase activity was normalized to the -galactosidase activ-
ity of a co-transfected reporter. The values presented are the mean of at
least five different experiments. Normalized luciferase activity units
are 103 in all experiments. C and D, expression of the Bcl-x(3.2)
reporter in FS cells in response to increasing concentrations of dexa-
methasone (C) or to various hormone treatments, 100 nM dexametha-
sone, and/or the GR antagonist RU 40555 (RU) (D).
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fragment, RE1, which encompasses all four putative GREs,
displayed the strongest transcriptional activity, followed by
RE2 and RE3. Importantly, these sequences also conferred
hormone responsiveness when co-transfected with a GR ex-
pression vector into COS-7 cells (Fig. 5E) although to a lesser
extent than a reporter construct driven by a consensus GRE
(TAT1, one copy of the GRE from the tyrosine aminotrans-
ferase gene promoter in front of the TK109 promoter). A con-
struct containing an unrelated sequence (consensus thyroid
response element, TK) upstream of the TK109-luciferase did not
respond to dexamethasone. These results confirm that dexa-
methasone-responsive sequences of the Bcl-x promoter lie
within (2944 to 2826) and (2330 to 2268).
Finally, two point mutations in positions known to be impor-
tant for GR-dependent transcription in the context of a consen-
sus GRE (35) were introduced in each of the three putative
GREs, and their effect on dexamethasone-dependent induction
of the Bcl-x promoter was determined in transient transfection
assays. Single and double combinations of these mutations
decreased Bcl-x inducibility by dexamethasone in an additive
fashion (data not shown), whereas introduction of two point
mutations in each of the putative GREs (Fig. 5F) resulted in
strong reduction of dexamethasone-dependent transcriptional
activity in FS cells (Fig. 5G). In NF cells the response to
dexamethasone is much weaker, but the inhibitory effect of
mutating the GREs was still detectable. Although mutation of
these binding sites does not abolish dexamethasone-dependent
transcriptional activation of the Bcl-x promoter in FS cells
totally, this was not surprising, because we know that the Bcl-x
promoter contains other weak proximal putative GREs (Fig.
5B), and it is still conceivable that there are further weak
putative GREs that remain unidentified. However, our results
suggest that the integrity of the three GREs we have identified
is required for GR-dependent activation of transcription.
GR Binds to the Bcl-x Promoter in Vitro and in Vivo—The
ability of GR to bind to the identified GRE sequences was
examined by gel mobility shift assays. We incubated nuclear
extracts from hormone-treated FS cells in the presence of la-
beled oligonucleotides containing either one of the putative
GREs (Fig. 5C, P1–3). A retarded complex was observed using
P1 (Fig. 6A, lane b), P2 (lane g), and P3 (lane j) that migrated
at the same position as that originated by binding of FS cell
extracts to the consensus GRE-TAT (lane m). This complex has
been shown to represent GR protein specifically bound to the
GRE sequences (22). Incubation with 50-fold excess of the
corresponding unlabeled oligonucleotides abolished binding to
these sequences (Fig. 6A, lanes c, f, k, and n), whereas 200-fold
excess of nonspecific unlabeled oligonucleotide had no effect
(lanes d, h, l, and o), confirming the specificity of the binding
reactions. The same experiment was performed with extracts
from all four stages of the tumorigenesis pathway, and as
expected from previous findings (22), GR binds to these se-
quences at all cell stages with similar efficiency (data not
shown). Furthermore, binding of GR to the labeled consensus
GRE (Fig. 6B, lane b) is disrupted by 50-fold excess of the
unlabeled putative P1 (lane c), P2 (lane d), and P3 (lane e),
which is as efficient as using the same molar excess of unla-
beled consensus GRE (S) (lane f). In the reverse experiment,
binding to all labeled putative GREs, P1, P2, and P3 (Fig. 6C,
lanes b, e, and h), could be abolished by competition with
unlabeled consensus GRE (S) (lanes c, f, and i). In summary,
these experiments demonstrate that GR can specifically bind in
vitro to non-consensus GRE sequences in the Bcl-x promoter.
To determine whether GR interacts directly with this region
of the Bcl-x promoter in vivo, we used the chromatin immuno-
precipitation assay. Using an antibody raised against GR to
immunoprecipitate sequences bound by GR, we observed in-
creased occupancy by GR at the Bcl-x promoter after addition of
dexamethasone (Fig. 7, compare lanes 7 and 8), whereas no
signal could be amplified from a fragment corresponding to a
control element from the Bak promoter, which lacks functional
GREs. These observations were dependent on the use of an
antibody raised against GR to immunoprecipitate efficiently
the sequences of the Bcl-x promoter containing putative GREs,
whereas a control antibody (also rabbit serum, against cyclin A)
failed to recruit either of the promoter sequences in a ligand-
dependent manner (lanes 5 and 6). Thus, GR binds to the
functional GREs sequences identified in the Bcl-x promoter in
vivo.
Exogenous Expression of Bcl-xL Reduces Apoptosis in FS
Cells—Apoptosis is reduced by dexamethasone in FS cells, and
this correlates with transcriptional activation of the Bcl-x pro-
moter and increased expression of the anti-apoptotic protein,
Bcl-xL. To determine whether enhanced Bcl-xL expression is
FIG. 5. Bcl-x promoter analysis. A, Bcl-x promoter fragments. Dex,
dexamethasone. B, activity of the Bcl-x luciferase constructs shown in A
in FS cells. The values presented are the mean of four different trans-
fection experiments done in duplicates. Cells were untreated (black
bars) or treated for 36 h with 100 nM dexamethasone (shaded bars). C,
putative dexamethasone-responsive sequences within the Bcl-x pro-
moter. D and E, activity of the Bcl-x constructs shown in C in FS cells
(D) and in COS-7 cells (E) with conditions as described in B. F, triple
mutant (mut) reporter resulting from the mutation of 2 bp in each of
the three GREs (P1, P2, and P3) in the Bcl-x(3.2) reporter construct.
G, transcriptional activity of the wild type (wt) and triple mutant
Bcl-x(3.2) reporters (mut) with conditions as described in B.
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sufficient to reduce apoptosis in FS cells, we transfected an
expression vector encoding Bcl-xL, driven by the cytomegalo-
virus promoter, into FS cells in the absence or presence of
dexamethasone. Transfection of this construct generated a
level of Bcl-xL protein expression similar to or higher than that
obtained by hormone treatment in FS cells transfected with the
cytomegalovirus vector alone (Fig. 8A). Dexamethasone did not
increase the level of Bcl-xL further. Determination of cell death
upon transfection with the Bcl-xL expression vector alone indi-
cated that the number of dead cells (Fig. 7B) and caspase-3
activity (Fig. 8C) were reduced significantly (p  0.005) com-
pared with that achieved by dexamethasone treatment of FS
cells transfected with vector alone (or untransfected; data not
shown). Importantly, Bcl-xL overexpression in the absence of
hormone had a similar effect in both assays, demonstrating
that Bcl-xL inhibits apoptosis in FS cells. The number of dead
cells (Fig. 8B) and caspase-3 activity (Fig. 8C) were further
reduced upon dexamethasone treatment (p  0.005) despite
apparently constant levels of Bcl-xL protein.
DISCUSSION
Apoptosis has been found to be widespread in many tumors
(36, 37) and yet limited in others (38). GR can display either
pro-apoptotic or anti-apoptotic activity depending on cell con-
text (39, 40). We show here that in the absence of glucocorti-
coids apoptosis increases during fibrosarcoma development,
whereas in the presence of dexamethasone it is reduced to
those levels found in the earlier stages of the tumorigenic
pathway.
Few studies of caspase activity during tumor development
have been reported. Caspase-3-like activity has been observed
to increase during the development of colorectal carcinoma
(41), thus representing a situation similar to that found in the
absence of glucocorticoids during fibrosarcoma development.
Although involved in some forms of apoptosis, caspase-1 also
promotes inflammatory responses by regulating cytokine sig-
naling (42). Increasing caspase-1 activity during fibrosarcoma
development may therefore have implications not only for ap-
optosis but also for inflammation.
Our results demonstrate that decreasing Bcl-xL expression
results primarily from decreasing Bcl-x transcription. This cor-
relates inversely with increasing transcription of the BPV-1
genome and E5, E6, and E7 oncogene expression in MF, AF,
and FS cells (21, 53). Both BPV-1 E6 and E7 oncoproteins
sensitize cells to apoptosis induced by tumor necrosis factor-
(43); thus it can be speculated that these proteins may inhibit
Bcl-x transcription. Notably, the angiogenic growth factor
bFGF increases Bcl-x expression in epithelial cells (44). Be-
FIG. 6. Gel retardation assays. in vitro DNA binding of GR from nuclear extracts of dexamethasone-treated FS cells. A, the various 32P
end-labeled oligonucleotides used as probes (P1–P3) are indicated at the top. Competition reactions were performed using 50-fold excess of the
corresponding unlabeled oligonucleotide (specific (same as labeled) probe (S)) (lanes c, f, k, and n) or 200-fold excess of a nonspecific oligonucleotide
(N) (lanes d, h, l, and o). B, a 32P end-labeled consensus GRE-TAT oligonucleotide used as probe. Competition reactions with 50-fold excess of
unlabeled oligonucleotides (P1–3, lanes c–e, respectively, as well as GRE, S, lane f) or nonspecific oligonucleotides (N, lanes g–i). C, labeled probes
are indicated at the top). Competition reactions were performed with unlabeled GRE (S, lanes c, f, and i) or nonspecific oligonucleotide (N, lanes
d, g, and j). The asterisk indicates the position of a nonspecific complex. Lane a (in A–C), and lanes e and i (in A) represent incubation in the absence
of extract.
FIG. 7. ChIP assay. Cells were untreated or were incubated for 1 h
with dexamethasone (Dex). Binding of GR to the Bcl-x promoter in FS
cells was determined in vivo with the ChIP assay (lanes 7 and 8). As
controls, sample lysates were also incubated with an antibody against
cyclin A (lanes 5 and 6) or without antibody (lane 2), and PCR ampli-
fications included primers designed to detect a control segment from the
endogenous Bak promoter that lacks functional GREs. Lane 1 is the
molecular weight marker; lanes 3 and 4 represent input signals ob-
tained from 0.5% input chromatin, whereas3% of the immunoprecipi-
tated material was amplified. IP Ab, immunoprecipitation antibody.
FIG. 8. Over-expression of Bcl-xL in FS cells. A, FS cells were
transfected with a Bcl-xL expression vector or control vector and treated
with 100 nM dexamethasone (Dex) for 48 h. Whole cell extracts were
analyzed for Bcl-xL protein expression. B, number of dead cells in
Bcl-xL-transfected FS cell cultures. Values represent the mean of 12
independent counts (104). C, caspase-3 enzyme activity in Bcl-xL-
transfected FS cells. Caspase activity is given in absorbance units
(103).
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cause the expression of bFGF becomes increasingly extracellu-
lar at the AF stage of fibrosarcoma development (45), it is
possible that decreasing levels of intracellular bFGF contribute
to decreasing Bcl-xL expression in AF and FS cells. In addition,
the transcription factor AP-1 has been proposed to inhibit
Bcl-xL expression (46), and therefore the increased expression
and activity of the AP-1 component proteins c-Jun and JunB in
AF and FS cells (22, 47) may also reduce Bcl-xL expression.
Increased Bcl-xL mRNA expression following glucocorticoid
treatment has been observed in human gastric cancer cells (6),
where enhanced Bcl-xL mRNA stability was found to represent
a part of the mechanism underlying the protective effect of
dexamethasone. However, dexamethasone does not affect the
stability of Bcl-xL mRNA in fibrosarcoma cells (53). The re-
ported increased expression of Bcl-xL mRNA in human myeloid
leukemic cells required 24 h of hormone treatment (48),
whereas we clearly detected up-regulation of Bcl-xL after 2 h of
dexamethasone treatment. Subsequent studies by other groups
have also demonstrated the importance of increasing Bcl-xL
expression for the inhibition of apoptosis by glucocorticoids in a
variety of cell types (3, 8, 31, 49). However, none of these
reports identified the mechanism by which GR might control
Bcl-x expression.
Further extending the initial observations of these studies,
we have demonstrated that the up-regulation of Bcl-xL expres-
sion by dexamethasone occurs at the transcriptional level and
is increased during fibrosarcoma development. The increased
expression of Bcl-xL is most likely achieved by specific binding
of GR to the identified GRE-like sequences within the Bcl-x
promoter. In fact, these sequences also confer hormone respon-
siveness to a heterologous promoter in COS-7 cells, indicating
that the presence of ligand-activated GR is sufficient to induce
Bcl-x transcription in other cell types. Furthermore, specific
activation of the Bcl-x promoter by dexamethasone requires the
cooperation of the various GREs identified, because deletion or
mutation of these elements results in a reduction in respon-
siveness. This observation supports the prediction made by
Nordeen and colleagues (35) that most natural response ele-
ments are suboptimal elements and that cooperativity among
these individually weak sites contributes to the inducibility of
the promoter. Because Bcl-x expression is higher in untreated
NF than in untreated FS cells, one possibility is that the Bcl-x
promoter is repressed in FS cells and that dexamethasone
treatment results in de-repression. Although this may be the
case, the reduced expression of Bcl-x in FS cells is unlikely to
involve GR binding to GREs in the Bcl-x promoter, because
their mutation does not affect transcription in the absence of
hormone.
Importantly, Bcl-xL is responsible for the ability of dexa-
methasone to inhibit apoptosis in fibrosarcoma cells, as shown
by ectopic expression of Bcl-xL. As expression of Bcl-xL de-
creases during fibrosarcoma development in the absence of
glucocorticoids, increasing up-regulation of Bcl-xL expression
by dexamethasone serves to maintain Bcl-xL levels during
tumor development, and thus apoptosis remains approximately
constant. In effect, Bcl-xL expression becomes increasingly de-
pendent on glucocorticoids during fibrosarcoma development.
Increased Bcl-xL expression and reduced apoptosis correlate in
FS cells with decreased caspase-3, but not caspase-1, activity in
response to glucocorticoids. Such a correlation has also been
reported by Messmer et al. (49). Furthermore, levels of apo-
ptosis in hormone-treated FS cells are comparable with those
in earlier cell types, despite the presence of higher caspase-1
activity. These data indicate that caspase-3 is likely to play a
more important role than caspase-1 in determining apoptosis
in FS cells.
It may be noteworthy that we also observed dexamethasone
regulation of Bcl-x expression in both normal and transformed
human mammary epithelial cells. Apoptosis of immortalized
mouse mammary epithelial cells can be decreased by dexa-
methasone treatment, associated with increased Bcl-x mRNA
expression, within 2 h of hormone treatment (8). Intriguingly,
an increase in Bcl-xL protein expression following dexametha-
sone treatment was readily detectable in transformed SK-BR-3
breast cancer cells but was lower in normal epithelial cells
(data not shown). This represents a parallel situation to that
observed during fibrosarcoma progression, where the ability of
hormone to induce Bcl-xL expression increases during tumor
development; it may reflect the ability of normal cells to limit,
or of tumor cells to enhance, regulation of gene expression by
specific steroid hormone receptors as has been suggested pre-
viously (22). Such a phenomenon may be a result of increased
expression of steroid hormone receptor co-factors during tumor
development, and indeed co-activators such as E6-AP and AIB1
are overexpressed in certain tumor types (50, 51).
It is interesting to consider that the discovery of regulation of
Bcl-xL expression by glucocorticoids during tumorigenesis may
have clinical relevance. Glucocorticoids such as dexamethasone
are used as anti-emetics in the treatment of several cancers.
One study has identified a strong negative correlation between
Bcl-xL expression and sensitivity to a wide variety of cytotoxic
agents in 60 cancer cell lines (18). Our results suggest that
Bcl-xL expression (and thus cell survival) may be promoted by
dexamethasone. Therefore, glucocorticoid treatment of tumors
may reduce the cytotoxic effects of chemotherapy on tumor cells
and may be contraindicated in those tumors with highly induc-
ible Bcl-xL expression. A similar situation may exist in ma-
lignant gliomas, where glucocorticoids have been reported to
interfere with chemotherapy response (52). Importantly,
indications that expression of Bcl-xL may be more glucocorticoid-
dependent in tumor cells than in normal cells suggest that
glucocorticoid therapy could have a certain degree of tumor
specificity.
The enhanced expression of Bcl-xL by GR during fibrosar-
coma development reflects the unexpected transition in the
transcriptional activity of GR and reveals an alternative mode
of regulation for steroid hormone receptors. In summary, in-
creasing GR transcriptional activity is likely to exert a protec-
tive effect by enabling the reduction of apoptosis at the tumor
stage of fibrosarcoma development and, therefore, prolonging
tumor cell survival.
Acknowledgments—We are very grateful to Gabriel Nun˜ez (Univer-
sity of Michigan Medical School, Ann Arbor) for providing the mouse
Bcl-x(3.2) reporter, to Leanne Wiedemann (Stowers Institute for Med-
ical Research, Kansas City, MO) for the human Bcl-xL cDNA, and to
Roussel-Uclaf for RU 40555. We also thank Ramon Roca (Institute of
Cancer Research, London) for help with various aspects of this work
and Francesca Buffa (Institute of Cancer Research, London) for help
with the statistical analysis. We very much appreciate Alan Ashworth
and Pascal Meier for their critical reading of the manuscript.
REFERENCES
1. Planey, S. L., and Litwack, G. (2000) Biochem. Biophys. Res. Commun. 279,
307–312
2. Smets, L. A., Salomons, G., and van den Berg, J. (1999) Adv. Exp. Med. Biol.
457, 607–614
3. Gorman, A. M., Hirt, U. A., Orrenius, S., and Ceccatelli, S. (2000) Neuroscience
96, 417–425
4. Pagliacci, M. C., Migliorati, G., Smacchia, M., Grignani, F., Riccardi, C., and
Nicoletti, I. (1993) J. Endocrinol. Invest. 16, 591–599
5. Evans-Storms, R. B., and Cidlowski, J. A. (2000) Endocrinology 141,
1854–1862
6. Chang, T. C., Hung, M. W., Jiang, S. Y., Chu, J. T., Chu, L. L., and Tsai, L. C.
(1997) FEBS Lett. 415, 11–15
7. Feng, Z., Marti, A., Jehn, B., Altermatt, H. J., Chicaiza, G., and Jaggi, R.
(1995) J. Cell Biol. 131, 1095–1103
8. Schorr, K., and Furth, P. A. (2000) Cancer Res. 60, 5950–5953
9. Beato, M., Herrlich, P., and Schutz, G. (1995) Cell 83, 851–857
10. Cole, T. J., Blendy, J. A., Monaghan, A. P., Schmid, W., Aguzzi, A., and Schutz,
Activation of Bcl-xL by GR during Tumorigenesis18028
 at Institute of Cancer Research on Septem
ber 12, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
G. (1995) Steroids 60, 93–96
11. Reed, J. C. (1999) J. Clin. Oncol. 17, 2941–2953
12. Raff, M. C. (1992) Nature 356, 397–400
13. Shi, Y. (2002) Mol. Cell 9, 459–470
14. Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Annu. Rev.
Biochem. 68, 383–424
15. Adams, J. M., and Cory, S. (2001) Trends Biochem. Sci. 26, 61–66
16. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999) Genes Dev. 13,
1899–1911
17. Evan, G., and Littlewood, T. (1998) Science 281, 1317–1322
18. Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C., and
Fornace, A. J., Jr. (2000) Cancer Res. 60, 6101–6110
19. Hanahan, D., and Weinberg, R. A. (2000) Cell 100, 57–70
20. Hanahan, D. (1988) Annu. Rev. Genet. 22, 479–519
21. Sippola-Thiele, M., Hanahan, D., and Howley, P. M. (1989) Mol. Cell. Biol. 9,
925–934
22. Vivanco, M. d. M., Johnson, R., Galante, P. E., Hanahan, D., and Yamamoto,
K. R. (1995) EMBO J. 14, 2217–2228
23. Grillot, D. A., Gonzalez-Garcia, M., Ekhterae, D., Duan, L., Inohara, N., Ohta,
S., Seldin, M. F., and Nunez, G. (1997) J. Immunol. 158, 4750–4757
24. Miesfeld, R., Godowski, P. J., Maler, B. A., and Yamamoto, K. R. (1987) Science
236, 423–427
25. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. (1991)
Oncogene 6, 1915–1922
26. Pascussi, J. M., Busson-Le Coniat, M., Maurel, P., and Vilarem, M. J. (2003)
Mol. Endocrinol. 17, 42–55
27. Lacey, M., Alpert, S., and Hanahan, D. (1986) Nature 322, 609–612
28. Woo, M., Hakem, R., Soengas, M. S., Duncan, G. S., Shahinian, A., Kagi, D.,
Hakem, A., McCurrach, M., Khoo, W., Kaufman, S. A., Senaldi, G., Howard,
T., Lowe, S. W., and Mak, T. W. (1998) Genes Dev. 12, 806–819
29. Alnemri, E. S., Fernandes-Alnemri, T., and Litwack, G. (1995) J. Biol. Chem.
270, 4312–4317
30. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R., and Thompson, C. B.
(2001) Genes Dev. 15, 1481–1486
31. Pecci, A., Scholz, A., Pelster, D., and Beato, M. (1997) J. Biol. Chem. 272,
11791–11798
32. Gonzalez-Garcia, M., Perez-Ballestero, R., Ding, L., Duan, L., Boise, L. H.,
Thompson, C. B., and Nunez, G. (1994) Development 120, 3033–3042
33. Boruk, M., Savory, J. G., and Hache, R. J. (1998) Mol. Endocrinol. 12,
1749–1763
34. Chandran, U. R., Attardi, B., Friedman, R., Zheng, Z., Roberts, J. L., and
DeFranco, D. B. (1996) J. Biol. Chem. 271, 20412–20420
35. Nordeen, S. K., Suh, B. J., Kuhnel, B., and Hutchison, C. D. (1990) Mol.
Endocrinol. 4, 1866–1873
36. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Br. J. Cancer 26, 239–257
37. Arends, M. J., McGregor, A. H., and Wyllie, A. H. (1994) Am. J. Pathol. 144,
1045–1057
38. Kaufmann, S. H., and Gores, G. J. (2000) Bioessays 22, 1007–1017
39. Tolosa, E., and Ashwell, J. D. (1999) Neuroimmunomodulation 6, 90–96
40. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P.,
Downward, J., and Evan, G. (1997) Nature 385, 544–548
41. Leonardos, L., Butler, L. M., Hewett, P. J., Zalewski, P. D., and Cowled, P. A.
(1999) Cancer Lett. 143, 29–35
42. Watson, R. W., Rotstein, O. D., Parodo, J., Bitar, R., Marshall, J. C., William,
R., and Watson, G. (1998) J. Immunol. 161, 957–962
43. Liu, Z., Liu, Y., Hong, Y., Rapp, L., Androphy, E. J., and Chen, J. J. (2002)
Virology 295, 230–237
44. Bryckaert, M., Guillonneau, X., Hecquet, C., Courtois, Y., and Mascarelli, F.
(1999) Oncogene 18, 7584–7593
45. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and
Hanahan, D. (1991) Cell 66, 1095–1104
46. Jacobs-Helber, S. M., Wickrema, A., Birrer, M. J., and Sawyer, S. T. (1998)
Mol. Cell. Biol. 18, 3699–3707
47. Bossy-Wetzel, E., Bravo, R., and Hanahan, D. (1992) Genes Dev. 6, 2340–2351
48. Lotem, J., and Sachs, L. (1995) Cell Growth & Differ. 6, 647–653
49. Messmer, U. K., Winkel, G., Briner, V. A., and Pfeilschifter, J. (2000) Br. J.
Pharmacol. 129, 1673–1683
50. Sivaraman, L., Nawaz, Z., Medina, D., Conneely, O. M., and O’Malley, B. W.
(2000) Breast Cancer Res. Treat. 62, 185–195
51. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan,
X. Y., Sauter, G., Kallioniemi, O. P., Trent, J. M., and Meltzer, P. S. (1997)
Science 277, 965–968
52. Weller, M., Schmidt, C., Roth, W., and Dichgans, J. (1997) Neurology 48,
1704–1709
53. Roca, R., Kypta, R. M., and Vivanco, M. d. M. (2003) Proc. Natl. Acad. Sci.
U. S. A. 100, 3113–3118
Activation of Bcl-xL by GR during Tumorigenesis 18029
 at Institute of Cancer Research on Septem
ber 12, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Duncan M. Gascoyne, Robert M. Kypta and Maria d. M. Vivanco
 LTranscriptionally Activating Bcl-x
Glucocorticoids Inhibit Apoptosis during Fibrosarcoma Development by
doi: 10.1074/jbc.M301812200 originally published online March 12, 2003
2003, 278:18022-18029.J. Biol. Chem. 
  
 10.1074/jbc.M301812200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/278/20/18022.full.html#ref-list-1
This article cites 53 references, 22 of which can be accessed free at
 at Institute of Cancer Research on Septem
ber 12, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
